VENLAFAXINE XR CAPSULE (EXTENDED RELEASE)
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
14-08-2012
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE)
Tillgänglig från:
RANBAXY PHARMACEUTICALS CANADA INC.
ATC-kod:
N06AX16
INN (International namn):
VENLAFAXINE
Dos:
75MG
Läkemedelsform:
CAPSULE (EXTENDED RELEASE)
Sammansättning:
VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 75MG
Administreringssätt:
ORAL
Enheter i paketet:
30/500
Receptbelagda typ:
Prescription
Terapiområde:
SELECTIVE SEROTONIN AND NOREPINEPHRINE-REUPTAKE INHIBITORS
Produktsammanfattning:
Active ingredient group (AIG) number: 0131294001; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2012-08-16
Produktens egenskaper
_ _
_ _
_VENLAFAXINE XR (venlafaxine hydrochloride extended-release capsules)
_
_Page 1 of 62_
PRODUCT MONOGRAPH
PR
VENLAFAXINE XR
(VENLAFAXINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES)
37.5, 75 AND 150 MG
VENLAFAXINE (AS VENLAFAXINE HYDROCHLORIDE)
Professed Standard
ANTIDEPRESSANT/ANXIOLYTIC
Ranbaxy Pharmaceuticals Canada Inc.
2680 Matheson Blvd. East, Suite 200 Date of Preparation: August 14,
2012
Mississauga, Ontario
Canada L4W 0A5
Submission Control No: 156578
_ _
_ _
_VENLAFAXINE XR (venlafaxine hydrochloride extended-release capsules)
_
_Page 2 of 62_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
17
DRUG INTERACTIONS
.........................................................................................................
31
DOSAGE AND ADMINISTRATION
.....................................................................................
36
OVERDOSAGE
.......................................................................................................................
40
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 41
STORAGE AND STABILITY
.................................................................................................
45
SPECIAL HANDLING INSTRUCTIONS
..............................................................................
45
DOSAGE FORMS, COMPOSITION AND PACKAGING
..............
Läs hela dokumentet
